% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Shahswar:277758,
      author       = {R. Shahswar and G. Beutel and R. Gabdoulline and A.
                      Schwarzer and A. Kloos and C. Koenecke and M. Stadler and G.
                      Gohring and Y. L. Behrens and Z. Li and L.-K. Dallmann and
                      P. Klement and C. Albert and M. Wichmann and Y. Alwie and A.
                      Benner$^*$ and M. Saadati and A. Ganser and F. Thol and M.
                      Heuser},
      title        = {{F}ludarabine, cytarabine, and idarubicin with or without
                      venetoclax in patients with relapsed/refractory acute
                      myeloid leukemia.},
      journal      = {Haematologica},
      volume       = {109},
      number       = {1},
      issn         = {0390-6078},
      address      = {Pavia},
      publisher    = {Ferrata Storti Foundation},
      reportid     = {DKFZ-2023-01475},
      pages        = {72-83},
      year         = {2024},
      note         = {2024 Jan 1;109(1):72-83},
      abstract     = {Treatment options for relapsed and refractory acute myeloid
                      leukemia patients (R/R AML) are limited. This retrospective
                      cohort study compares safety and efficacy of fludarabine,
                      cytarabine, and idarubicin (FLA-IDA) with or without
                      venetoclax in patients with R/R AML. Thirty-seven and 81
                      patients received one course FLA-IDA with or without a 7-day
                      course of venetoclax, respectively. The overall response
                      rate (ORR) was significantly higher in FLAVIDA compared to
                      FLA-IDA treated patients $(78\%$ vs. $47\%;$ P=0.001), while
                      MRD was negative at a similar proportion in responding
                      patients $(50\%$ vs. $57\%),$ respectively. Eightyone
                      percent and $79\%$ of patients proceeded to allogeneic
                      hematopoietic cell transplantation (alloHCT) or donor
                      lymphocyte infusion (DLI) after FLAVIDA and FLA-IDA,
                      respectively. Event-free and overall survival were similar
                      in FLAVIDA and FLA-IDA treated patients. Refractory patients
                      could be salvaged more successfully after FLA-IDA compared
                      to FLAVIDA pretreatment. Neutrophil and platelet recovery
                      times were similar in the venetoclax and the control group.
                      In conclusion, short-term venetoclax in combination with
                      FLA-IDA represents an effective treatment regimen in R/R AML
                      identifying chemosensitive patients rapidly and inducing MRD
                      negative remission in a high proportion of R/R AML
                      patients.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37470150},
      doi          = {10.3324/haematol.2023.282912},
      url          = {https://inrepo02.dkfz.de/record/277758},
}